References
- Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther 2002; 7: 165–74
- Marcelin AG, Cohen-Codar I, King MS, Colson P, Guillevic E, Descamps D, et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother 2005; 49: 1720–6
- Kaplan SS, Hicks CB. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. J Antimicrob Chemother 2005; 56: 273–6
- DeJesus, E, LaMarca, A, Sension, M, Beltran, C, Yeni, P. The Context Study: Efficacy and Safety of GW433908/RTV in PI experienced subjects with virological failure (24 weeks results). 10th Conference on Retroviruses and Opportunistic Infections. Abstract 178. February, 10–14, 2003. Boston, MA, USA.
- Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB., et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2004; 48: 116–23
- Chapman TM, Plosker GL, Perry CM. Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs 2004; 64: 2101–24
- Masquelier, B, Breilh, Neau D, Lawson-Ayayi, S, Lavignolle, V, Ragnaud, JM, , et al. Human immunodeficiency virus type 1 and pharmacokinetic determinants of the virological response to lopinavir-ritonavir containing therapy in protease inhibitors experienced patients. Antimicrob Agents Chemother 2002;46:2926–32.
- Quercia R, Garnier E, Ferre V. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs 2005; 65: 633–59
- Clevenbergh P, Boulme R, Kirstetter M, Dellamonica P. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients. HIV Med 2004; 5: 284–8
- Marcelin AG, Affolabi D, Lamotte C, Mohand HA, Delaugerre C, Wirden M, et al. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. J Med Virol 2004; 74: 16–20
- Masquelier, B, Assoumou, KL, Descamps, D, Bocket, L, Cottalorda, J, Ruffault, A, , et al. Genotypic determinants of the virological response to fosamprenavir/ritonavir in protease inhibitors experienced patients. XV International HIV drug resistance workshop: basic principles and clinical implications, 13–17, June, 2006, Sitges, Spain, abstract 91.
- van Laethem K, De Luca A, Antinori A, Cingolani A, Perno CF, Vandamme AM. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther 2002; 7: 123–9
- De Luca A, Cingolani A, Di Giambenedetto S, Trotta MP, Baldini F, Rizzo MG, et al. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003; 187: 1934–43
- Johnson AV, Brun-Vézinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, et al. Update of the Drug Resistance Mutations in HIV-1: Top HIV Med 2006; 14: 125–30